Medical Communications
FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy
May 11, 2023 Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy
Sobi acquires CTI BioPharma Corporation for $1.7bn
May 10, 2023 Medical Communications CTI, acquisition, sobi
Thermo Fisher and Pfizer collaborate on NGS-based cancer tests
May 10, 2023 Medical Communications Cancer, NGS, Oncology, Pfizer, Thermo Fisher Scientifitic, oncology
Pharmacists in England given wider prescribing powers to relieve GP pressure
May 9, 2023 Medical Communications GP, NHS England, pharmacists
AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death
May 9, 2023 Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure
CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates
May 9, 2023 Medical Communications CureVac, GSK, Virology, clinical trial, mrna, vaccines
FDA accepts sNDA for Optinose’s XHANCE
May 5, 2023 Medical Communications Ear Nose & throat, FDA, Nasal Spray, optinose, sNDA
Nanobiotix enters final contract negotiations with major pharma company
May 5, 2023 Medical Communications FDA, Oncology, nanobiotix, oncology
Cognixion receives FDA Breakthrough Device Designation for assisted communication device
May 5, 2023 Medical Communications Cognixion, FDA, Neurology, brain computer interface, breakthrough device designation, neuroscience
PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial
May 4, 2023 Medical Communications ADHD, Akili, Neurology, PureTech Health, clinical trials
FDA approves world’s first RSV vaccine
May 4, 2023 Medical Communications FDA, RSV, Vaccine, Virology
NICE recommends Otsuka’s Lupkynis (voclosporin) in combination treatment for active lupus nephritis
May 4, 2023 Medical Communications MHRA, NICE, Nephrology, Otsuka Pharmaceuticals, lupus nephritis
Avadel Pharmaceuticals granted FDA final approval for narcolepsy drug
May 3, 2023 Medical Communications FDA, FDA Approval, Neurology, avadel pharmaceuticals, narcolepsy, new drug approvals
Tempus receives FDA Premarket Approval for in vitro diagnostic scan
May 3, 2023 Medical Communications Diagnostics, FDA, Oncology, Tempus, in vitro
GSK’s RSV vaccine candidate gains positive EMA CHMP opinion
April 27, 2023 Medical Communications
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
